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ABSTRACT The aim of this study was to present our experience 
in rituximab therapy in patients with childhood-onset systemic 
lupus erythematosus, lupus nephritis, and ANCA-associated vas-
culitis. We conducted a retrospective clinical chart review of all 
patients treated with rituximab in the time period from Janu-
ary 2009 to December 2015. Eight patients (3 boys and 5 girls) 
aged 8 to 15 at the onset of disease were treated with rituximab. 
Remission of disease was accomplished in 4 patients with child-
hood-onset systemic lupus erythematosus and lupus nephritis, a 
partial improvement was achieved in 1 patient with childhood-
onset systemic lupus erythematosus and lupus nephritis as well 
as in 2 patients with vasculitis, while in one patient with vascu-
litis treatment with rituximab showed no effect and the patient 
died due to Candida sepsis. Reduction of corticosteroid doses 
was enabled by rituximab treatment. Rituximab appeared to be 
a safe and efficient therapeutic option in severe cases of child-
hood-onset systemic lupus erythematosus or ANCA-associated 
vasculitis that failed to respond to conventional therapy or as a 
rescue therapy in life-threatening conditions. 
KEY WORDS: systemic lupus erythematosus, vasculitis, child, 
adolescent
INTRODUCTION
Systemic autoimmune diseases such as systemic 
lupus erythematosus (SLE), different forms of vascu-
litis, antiphospholipid syndrome, and others often 
involve multiple organs. The skin is often affected in 
these patients, and rash can be the first symptom of 
disease. Such cases can be a real therapeutic chal-
lenge if patients are refractory to conventional treat-
ment or develop severe vital organ involvement and 
life-threatening conditions. There are only a few treat-
ment options that can achieve a rapid effect in these 
situations: high dose corticosteroids, cyclophospha-
mide, intravenous immunoglobulin (IVIG), plasma-
pheresis, and rituximab (RTX) (1).
Rituximab is a chimeric monoclonal mouse-hu-
man antibody that reacts with the B-cell CD20 recep-
tor present on pre-B and mature B-cells, but not on 
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stem cells or plasma cells, causing B-cell depletion 
(2). It was originally used in Hodgkin B-cell lymphoma 
treatment and was later approved for rheumatoid ar-
thritis and ANCA-associated vasculitis (AAV) and used 
off-label in many other autoimmune diseases, espe-
cially SLE (3).
There are not many reports of RTX efficacy in chil-
dren with autoimmune diseases refractory to conven-
tional therapy protocols and there are no clear treat-
ment guidelines (1,4-9). The aim of this study was to 
present our experience in RTX treatment of children 
with refractory autoimmune diseases.
PATIENTS AND METHODS
We conducted a retrospective clinical chart review 
of all patients treated with RTX at the Department of 
Pediatrics, Division of Rheumatology and Immunol-
ogy, University Hospital Centre Zagreb in the time 
period from January 2009 to December 2015. Pa-
tients with failure of conventional treatment with 
high doses of corticosteroids, cyclophosphamide, 
and other cytotoxic and antimetabolic agents as 
well as plasmapheresis were defined as treatment 
refractory. We collected general demographic, epi-
demiological, laboratory, and clinical data, observed 
and followed RTX-related as well as disease- and 
other medication-related complications during 
the post-RTX application follow-up and response 
to treatment. In patients with childhood-onset SLE 
(cSLE), response was defined as remission if the Sys-
temic Lupus Erythematosus Disease Activity Index 
(SLEDAI) score after 6 months was 2 or less, as partial 
improvement if SLEDAI score was 3 or higher after 
6 months but at least 50% lower than before treat-
ment with RTX, and as no effect for patients who did 
not meet those criteria (10,11). We assessed patients 
with vasculitis with the Paediatric Vasculitis Activity 
Score (PVAS) and defined remission as PVAS score 
0 and no signs of disease damage, partial improve-
ment as PVAS score reduction of at least 50% or pres-
ence of disease damage while the score was 0, and 
no effect for patients who do not meet those criteria 
(12). Failed conventional treatment was defined as 
the inability of achieving remission of disease or se-
vere deterioration of disease that was previously in 
remission.
Statistical analysis
Continuous variables were presented as mean 
and standard deviation (SD) or median with inter-
quartile range (IQR). Analyses were performed using 
Microsoft Excel 2016.
RESULTS
During the time period investigated in this study, 
8 patients were treated with rituximab, of which 3 
boys and 5 girls. Average age at disease onset was 
11.75 years (SD 2.49). Four patients were treated due 
to cSLE and LN, 1 had cSLE and autoimmune hepatitis 
(AH), and 3 were suffering from different forms of vas-
culitis (2 had AAV and 1 had Takayasu arteritis) (Table 
1). Patients had renal, cardiovascular, respiratory, and 
central nervous system involvement. Six patients had 
renal involvement, four of them lupus nephritis, and 
two had renal complications of vasculitis (Table 1). The 
average time between the beginning of conventional 
therapy and RTX introduction was 16.88 months (SD 
25.15 months), with a median of 4 months (IQR 1-22 
months). One of the patients with cSLE was treated 
with conventional therapy for 6 years and was in re-
mission, and had a severe flare of disease after 6 years 
that was refractory to conventional treatment when 
we decided to treat him with RTX.
Failed conventional treatment included corti-
costeroids, non-steroid anti-inflammatory drugs, 
hydroxychloroquine, methotrexate, cyclophospha-
mide, azathioprine, mycophenolate mofetil, and 
plasmapheresis (Table 2). In all cases, rituximab was 
introduced due to the ineffectiveness of conven-
tional therapy in inducing remission of the disease or 
deterioration of previously well-controlled disease. 
In 7 patients, rituximab was administered in a dose 
2×750 mg/m2, (max. 1 g), that was combined with cy-
clophosphamide “mini pulses” (350 mg/m2), and in 1 
patient it was administered in 4 doses of 375 mg/m2 
(Table 2). Due to the flare of disease in one patient 
with cSLE and LN, rituximab treatment was repeated 
after 3 years (4×375 mg/m2) with complete remission 
of the disease achieved once again. The treatment ef-
fect was measured with SLEDAI and PVAS scores (Ta-
ble 1). Remission was induced in 4 out of 8 patients, all 
of them with cSLE and LN, and partial improvement 
was achieved in another 3, 1 with cSLE and LN, and 2 
with vasculitis. One patient with AAV, whose condi-
tion was extremely severe when she was admitted to 
our Department, died due to Candida sepsis within 
2 months of rituximab administration. Corticosteroid 
doses were reduced or discontinued in all of the pa-
tients after RTX treatment (Table 2). The CD20 level 
was unmeasurable in most of the patients 6 months 
after treatment with RTX, showing the prolonged im-
munosuppression effect of RTX. Average follow-up 
period after RTX was 49.1 months (SD 26.0), during 
which time 3 patients sustained remission, one had a 
flare of disease after 3 years of remission, which was 
induced again after repeated RTX treatment. Three 
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patients showed partial improvement and 1 patient 
showed no response to therapy and died (Table 1). 
Three patients developed herpes zoster infection 
after therapy with RTX that was successfully treated 
with acyclovir, and 1 developed cellulitis and throm-
bophlebitis. One patient died because of Candida 
sepsis that developed 1 month after RTX treatment.
There were several disease complications or side-
effects of therapy with other medications (such as 
corticosteroids, etc.): 1 patient had end-stage renal 
disease followed by a kidney transplant. Two pa-
tients sustained pathological bone fractures, 2 had 
neurological complications (posterior reversible 
encephalopathy, CNS vasculitis). One patient had a 
Cushingoid appearance, and 1 had total obstruction 
of the left subclavian artery as well as stenosis of the 
left carotid artery and thoracic aorta combined with 
hypertension. The patient who died had renal failure 
and pulmonary hemorrhage. 
Two patients did not have any complications or 
side-effects during the follow-up period (Table 2).
DISCUSSION
RTX is used in the treatment of many autoimmune 
diseases, either as an alternative therapy regimen in 
patients with poorly controlled diseases or as a ste-
roid-sparing agent in patients with steroid-depen-
dent diseases. It is also used as a rescue therapy in 
life-threatening conditions (1,13-16). Although there 
are numerous reports of the safety and efficiency of 
RTX in those diseases, some well-known controlled 
trials failed to show the superiority of RTX as an add-
on therapy to standard protocol (1,7,9,15-23).
In our study, 4 out of 8 patients achieved remis-
sion following RTX treatment, and 3 patients showed 
partial improvement, while 1 patient showed no ef-
fect of RTX therapy and eventually died. One of 4 pa-
tients with remission experienced a flare of disease 
during the follow-up period, which was successfully 
treated with repeated RTX treatment. All of our pa-
tients were treated with RTX after a failure of conven-
tional treatment protocols. Side-effects that occurred 
in our patients (sepsis, herpes zoster, cellulitis, throm-
bophlebitis) resemble those most often described in 
the literature (6).
Although controlled trials such as Lupus Nephri-
tis with Rituximab (LUNAR) and Exploratory Phase 
II/III SLE Evaluation of Rituximab (EXPLORER) failed to 
show the expected effectiveness of RTX in patients 
with SLE for reasons that are beyond the scope of 
this study, use of RTX in treatment protocols based 
on induction of remission with RTX and avoiding pro-
longed use of corticosteroids such as in the Trial of 
Rituximab and Mycophenolate Mofetil Without Oral 
Steroids for Lupus Nephritis (RITUXILUP) showed RTX 
was effective and safe choice (3,8,9,17-19,24). A re-
cent systemic review showed improvements in renal, 
neuropsychiatric, and hematological manifestations, 
disease activity, and complement and anti-double-
stranded Desoxy-Nucleo-Adenosine antibodies level, 
with a steroid-sparing effect in patients with cSLE 
treated with RTX (5). Our results showed the effective-
ness of RTX in the treatment of severely ill patients 
recalcitrant to conventional treatment, confirming 
results of similar studies, although no definite con-
clusions about effectiveness can be drawn because 
of the small number of patients (1,7,13-16,20,21). We 
achieved better results in patients treated due to cSLE 
and LN, where we induced remission in 4 patients, 
whereas in patients with AAV we only accomplished 
partial improvement. One patient with vasculitis had 
a PVAS score of 0 after treatment with RTX, but due to 
substantial damage caused by the disease we consid-
ered her as just a partial improvement. 
Generally, there are not as many evidence-based 
studies considering AAV treatment with rituximab in 
the pediatric population as in adults, and many pedi-
atric rheumatologists use adult treatment guidelines 
for treating their patients. There is both need and in-
terest for creating consensus treatment guidelines 
for the pediatric population with AAV (25). Recently, 
the European League Against Rheumatism/European 
Renal Association – European Dialysis and Transplant 
Association (EULAR/ERA-EDTA) recommendations for 
the management of AAV recommended treatment 
with a combination of glucocorticoids and either 
cyclophosphamide or rituximab for remission-induc-
tion of new-onset organ-threatening or life-threaten-
ing AAV as well as for a major relapse of organ-threat-
ening or life-threatening diseases (26). Studies like 
Rituximab for ANCA – associated vasculitis (RAVE) 
and Rituximab versus cyclophosphamide in ANCA 
– associated vasculitis (RITUXVAS) found an impor-
tant role of RTX in the induction of remission, and the 
Rituximab vasculitis maintenance study (RITAZAREM) 
and Maintenance using rituximab in remission after 
vasculitis (MAINRISTAN) studies showed RTX was ef-
fective in maintenance of remission in AAV (27-29).
One of the possible benefits of RTX treatment is 
a reduction in doses of other medications and their 
subsequent side-effects. In our study, RTX treatment 
enabled us to reduce doses of corticosteroids or 
even completely discontinue its use. Similar experi-
ences were also reported in other studies, while some 
novel treatment protocols such as RITUXILUP com-
pletely avoid oral steroids in maintenance treatment 
(3,7,24).
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CONCLUSION
There are numerous case reports and open-label 
studies showing the effectiveness and safety of RTX 
in severely ill patients suffering from different types 
of autoimmune diseases which are refractory to con-
ventional therapy. Even though large controlled stud-
ies failed to show the superiority of RTX over placebo, 
we believe that RTX has an important place as a safe 
and efficient treatment option in pediatric patients 
with severe cases of childhood-onset SLE or AAV re-
fractory to conventional therapy, as a rescue therapy 
in a life-threatening conditions, or as an alternative 
to highly toxic agents such as cyclophosphamide in 
young patients.
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